TITLE

Cost-Effectiveness Analysis of the Addition of Rituximab to CHOP in Young Patients with Good-Prognosis Diffuse Large-B-Cell Lymphoma

AUTHOR(S)
Ferrara, Felicetto; Ravasio, Roberto
PUB. DATE
January 2008
SOURCE
Clinical Drug Investigation;2008, Vol. 28 Issue 1, p55
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
BACKGROUND: and objective: Diffuse large-B-cell lymphoma (DLBCL) is an aggressive form of lymphoma. It accounts for 30–40% of all new cases of non-Hodgkin’s lymphoma and is the subtype with the highest overall incidence. Before the development of monoclonal antibodies, the standard treatment of newly diagnosed DLBCL was based on combination therapy with cyclophosphamide, doxorubicin, vincristine and prednisone (CHOP). Current treatment consists of the combination of CHOP and the monoclonal antibody rituximab (R-CHOP regimen), with recovery rates of 70%. The aim of this study was to compare the efficacy (survival) and direct medical costs of two chemotherapy regimens, R-CHOP and CHOP, in the treatment of DLBCL in young patients with a good prognosis. METHODS: A decision-analysis model with tree structure was used to compare R-CHOP and CHOP in the treatment of young patients with DLBCL from the perspective of the Italian National Health Service. Patients entered at the root of the tree and followed one of the six possible therapeutic pathways. After receiving one of the two chemotherapy treatments (R-CHOP or CHOP) for 5 months, patients could have a complete response or not. In the presence of no response, patients underwent rescue therapy. In the case of relapse after 3 years’ follow-up (following an initial complete response at 5 months), patients were given rescue therapy. The model provided an estimate of mean survival (life-years gained [LYG]) and mean costs (direct medical costs) over a period of 3 years. Both survival and costs were discounted at a rate of 3%. Costs were in €, year 2007 values. Several sensitivity analyses were carried out with varying clinical parameters. RESULTS: The LYG with the R-CHOP regimen was higher (2.697 LYG per patient) than with the CHOP regimen (2.517 LYG per patient). When taking into account the cost of rescue therapy, the overall mean treatment cost per patient was lower with the R-CHOP regimen (€22 113.44) than with the CHOP regimen (€22 831.17). Sensitivity analyses showed that the incremental cost-effectiveness ratios per LYG for complete response at 5 months (€16 816.00) and for relapse-free survival at 3 years (€11 967.12) were below the internationally accepted threshold (€50 000). Furthermore, for survival at 3 years, R-CHOP was confirmed as the dominant therapy (lower expected mean costs, higher number of LYG). CONCLUSIONS: Our study demonstrated the clinical and economic benefits of adding rituximab to a CHOP chemotherapy regimen in young patients who present with DLBCL with good prognosis. The higher costs associated with rituximab were offset by the significantly lower rescue therapy costs. Further studies that include patients with unfavourable prognosis are needed to confirm these findings.
ACCESSION #
28329324

 

Related Articles

  • Rituximab retherapy in patients with relapsed aggressive B cell and mantle cell lymphoma. Borgerding, Andrea; Hasenkamp, Justin; Glaß, Bertram; Wulf, Gerald; Trümper, Lorenz // Annals of Hematology;Mar2010, Vol. 89 Issue 3, p283 

    Neither effective salvage regimens nor the outcome and response to retherapy with rituximab containing chemotherapy have been defined for rituximab pre-treated patients with relapsing aggressive lymphoma. We report here a single-centre retrospective outcome analysis of second-line...

  • Rituximab therapy in malignant lymphoma. Coiffier, B. // Oncogene;5/28/2007, Vol. 26 Issue 25, p3603 

    Rituximab is the first monoclonal antibody to have been registered for the treatment of B-cell lymphomas. Randomized studies haves demonstrated its activity in follicular lymphoma (FL), mantle cell lymphoma and diffuse large B-cell lymphoma (DLBCL) in untreated or relapsing patients....

  • Genetic lesions in diffuse large B-cell lymphomas. Testoni, M.; Zucca, E.; Young, K. H.; Bertoni, F. // Annals of Oncology;Jun2015, Vol. 26 Issue 6, p1069 

    Diffuse large B-cell lymphoma (DLBCL) is the most common lymphoma in adults, accounting for 35%-40% of all cases. The combination of the anti-CD20 monoclonal antibody rituximab with anthracycline-based combination chemotherapy (R-CHOP, rituximab with cyclophosphamide, doxorubicin, vincristine...

  • An uncontrolled trial of rituximab for antibody associated paraneoplastic neurological syndromes. Shams'ili, Setareh; De Beukelaar, Janet; Gratama, Jan; Hooijkaas, Herbert; Van Den Bent, Martin; Van't Veer, Mars; Sillevis Smitt, Peter // Journal of Neurology;Jan2006, Vol. 253 Issue 1, p16 

    Anti-CD20 monoclonal antibody (rituximab) is effectively used in the treatment of B-cell lymphomas. Recent reports in the literature suggest that antibody associated autoimmune disorders may respond to rituximab. We therefore treated nine patients with anti-Hu or anti-Yo associated...

  • B-Cell Lymphoma With Intermediate- to High-Grade Features and Different Immunophenotypic Profiles Involving Separate Anatomic Sites With a Good Response to R-CHOP. Ron Lee; Christine Green; O. Negrea; Sarah Dodson; Sara Farrell; James Hewitt; Toni Jago; Chris Ramsey; Tracey Cato; Eric Crawford; Donald Henley; Mary Phelan; Nicholas Potter // Laboratory Medicine;Feb2009, Vol. 40 Issue 2, p79 

    The occurrence of B-cell lymphoma with intermediate- to high-grade features and different immunophenotypic profiles involving separate anatomic sites is uncommon. We describe such a case and present results of ancillary studies that characterized this B-cell lymphoma. The patient was treated...

  • Non-Hodgkin Lymphoma.  // Current Medical Literature: Leukemia & Lymphoma;2010, Vol. 18 Issue 1, p20 

    This article reviews several articles on non-Hodgkin lymphoma, including "Phase I Study of the Humanized Anti-Cd40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's lymphoma," by R. Advani, "Pre-Emptive Treatment With Rituximab of Molecular Relapse After Autologous Stem...

  • Resistance to Rituximab Therapy and Local BAFF Overexpression in Sjögren's Syndrome-Related Myoepithelial Sialadenitis and Low-Grade Parotid B-Cell Lymphoma. Quartuccio, Luca; Fabris, Martina; Moretti, Massimo; Barone, Francesca; Bombardieri, Michele; Rupolo, Maurizio; Lombardi, Sandra; Pitzalis, Costantino; Beltrami, Carlo Alberto; Curcio, Francesco; de Vita, Salvatore // Open Rheumatology Journal;2008, Vol. 2, p38 

    Objective: B-cell expansion is a key feature of Sjögren's syndrome (SS). Accordingly, several studies have reported the benefits of B-cell depletion with anti-CD20 monoclonal antibody (Rituximab) in the treatment of glandular and extraglandular manifestations of SS. Patients with SS are at...

  • I Tositumomab: A Viewpoint by Michael L. Grossbard. Grossbard, M.L. // BioDrugs;2000, Vol. 14 Issue 3, p203 

    Discusses the approval of an unconjugated anti-CD20 antibody rituximab for the treatment of patients with relapsed follicular and low grade non-Hodgkin's lymphoma. Use of monoclonal antibody therapies in laboratories; Conjugation of antibodies with radioisotopes to permit the targeted delivery...

  • Rituximab: A Review of its Use in Chronic Lymphocytic Leukaemia, Low-Grade or Follicular Lymphoma and Diffuse Large B-Cell Lymphoma. Keating, Gillian M. // Drugs;2010, Vol. 70 Issue 11, p1445 

    Rituximab (MabThera®, Rituxan®) is a chimeric mouse anti-human CD20 monoclonal antibody. This article reviews the use of intravenous rituximab in the treatment of chronic lymphocytic leukaemia (CLL), low-grade or follicular lymphoma, and diffuse large B-cell lymphoma. The addition of...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics